ANI Pharma proposes $250M convertible notes due 2029; to repay term loan

ANI PHARMACEUTICALS INC

Offering $250M in Convertible Senior Notes due Sept 1, 2029; underwriters option for additional $37.5M.
Proceeds used to repay existing senior secured term loan; new $325M delayed draw term loan and $75M revolver planned.
Capped call transactions expected to reduce dilution on conversion of notes.
Interest rate, conversion rate, and other terms to be set at pricing.
Notes unsecured; redemption at ANI's option after Sept 1, 2027 under certain conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.